Advertisement

Cancer Causes & Control

, Volume 30, Issue 5, pp 477–488 | Cite as

Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data

  • Dima Dandachi
  • Quinn T. Ostrom
  • Insun Chong
  • Jose A. Serpa
  • Thomas P. Giordano
  • Carol Kruchko
  • Jill S. Barnholtz-Sloan
  • Nathan Fowler
  • Rivka R. Colen
  • Fanny E. MorónEmail author
Original Paper

Abstract

Purpose

Primary central nervous system lymphoma (PCNSL) in patients living with HIV (PLWH) is a distinct entity; however, the management is adopted from patients without HIV. The study aims to examine the differences in presentation, treatment, and outcomes of PCNSL patients with or without HIV.

Methods

We retrospectively compared the characteristics of 144 patients with PCNSL with and without HIV, and analyzed factors associated with overall and progression-free survival. Results were compared to the Central Brain Tumor Registry of the United States (CBTRUS) and the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) system.

Results

Among all patients with PCNSL, 19% had HIV. PLWH were younger (38 vs. 63 years; p < 0.01) and more likely to be African American (59% vs. 7%; p < 0.01) and male (74% vs. 49%; p = 0.02) than patients without HIV. PLWH were more likely to have multiple lesions (67% vs. 43%; p = 0.02), hemorrhage (59 vs. 37%; p = 0.03), and peripheral rim enhancement (57% vs. 7%; p < 0.01) on imaging; to receive palliative care (15% vs. 2%) or whole brain radiation (63% vs. 3%); and less likely to receive chemotherapy (22% vs. 95%) (p < 0.01). Twenty-four patients, none PLWH, underwent stem cell transplant. Not receiving transplant was an independent factor in mortality and disease progression. Our cohort of patients, compared to the national database, were younger (60 vs. 65 years), 58% were white vs. 75%, and had longer median overall survival 43 vs. 25 months.

Conclusion

Epidemiology, imaging, and treatment options for patients with PCNSL with and without HIV differ, but HIV was not an independent factor of mortality or disease progression. More efforts are needed to improve access to research and treatment options for PLWH with PCNSL.

Keywords

Primary central nervous system lymphoma HIV Stem cell transplant Incidence Prognosis Treatment 

Notes

Acknowledgments

We thank the Department of Scientific Publications at The University of Texas MD Anderson Cancer Center for editorial assistance.

Funding

QTO is supported by a Research Training Grant from the Cancer Prevention and Research Institute of Texas (CPRIT; RP160097T). Funding for the Central Brain Tumor Registry of the United States (CBTRUS) was provided by the U.S. Centers for Disease Control and Prevention (CDC) under Contract No. 2016-M-9030, the American Brain Tumor Association, The Sontag Foundation, Novocure, AbbVie, the Musella Foundation, Alex’s Lemonade Stand Foundation, as well as private, and in-kind donations. Contents are solely the responsibility of the authors and do not necessarily reflect the official views of the CDC or the VA.

Compliance with ethical standards

Conflict of interest

All authors have read and approved this manuscript and have no conflicts of interest to declare.

References

  1. 1.
    O’Neill BP, Decker PA, Tieu C, Cerhan JR (2013) The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin’s lymphoma. Am J Hematol 88:997–1000CrossRefGoogle Scholar
  2. 2.
    Grommes C, DeAngelis LM (2017) Primary CNS lymphoma. J Clin Oncol 35:2410–2418CrossRefGoogle Scholar
  3. 3.
    Matinella A, Lanzafame M, Bonometti MA, Gajofatto A, Concia E, Vento S et al (2015) Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study. J Neurol 262:1317–1327CrossRefGoogle Scholar
  4. 4.
    Malikova H, Koubska E, Weichet J, Klener J, Rulseh A, Liscak R et al (2016) Can morphological MRI differentiate between primary central nervous system lymphoma and glioblastoma? Cancer Imaging 16:40CrossRefGoogle Scholar
  5. 5.
    Lloyd IE, Clement PW, Salzman KL, Jensen RL, Salama ME, Palmer CA (2015) An unusual and challenging case of HIV-associated primary CNS Lymphoma with Hodgkin-like morphology and HIV encephalitis. Diagn Pathol 10:152CrossRefGoogle Scholar
  6. 6.
    Bayraktar S, Bayraktar UD, Ramos JC, Stefanovic A, Lossos IS (2011) Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol 101:257–265CrossRefGoogle Scholar
  7. 7.
    Yanagisawa K, Tanuma J, Hagiwara S, Gatanaga H, Kikuchi Y, Oka S (2013) Epstein-Barr viral load in cerebrospinal fluid as a diagnostic marker of central nervous system involvement of AIDS-related lymphoma. Intern Med 52:955–959CrossRefGoogle Scholar
  8. 8.
    Tang YZ, Booth TC, Bhogal P, Malhotra A, Wilhelm T (2011) Imaging of primary central nervous system lymphoma. Clin Radiol 66:768–777CrossRefGoogle Scholar
  9. 9.
    Westwood TD, Hogan C, Julyan PJ, Coutts G, Bonington S, Carrington B et al (2013) Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients. Eur J Radiol 82:e374–e379CrossRefGoogle Scholar
  10. 10.
    Han CH, Batchelor TT (2017) Diagnosis and management of primary central nervous system lymphoma. Cancer 123:4314–4324CrossRefGoogle Scholar
  11. 11.
    Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A et al (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266–272CrossRefGoogle Scholar
  12. 12.
    Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ (2011) Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 105:1414–1418CrossRefGoogle Scholar
  13. 13.
    Liu J, Wang Y, Liu Y, Liu Z, Cui Q, Ji N et al (2017) Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: analysis of 89 cases. Oncol Lett 14:5505–5512Google Scholar
  14. 14.
    Gopal S, Martin KE, Richards KL, Eron JJ (2012) Clinical presentation, treatment, and outcomes among 65 patients with HIV-associated lymphoma treated at the University of North Carolina, 2000–2010. AIDS Res Hum Retroviruses 28:798–805CrossRefGoogle Scholar
  15. 15.
    Han CH, Batchelor TT (2017) Primary central nervous system lymphoma. Continuum 23(6, Neuro-oncology):1601–1618Google Scholar
  16. 16.
    Schorb E, Finke J, Ferreri AJ, Ihorst G, Mikesch K, Kasenda B et al (2016) High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma: a randomized phase III trial (MATRix). BMC Cancer 16:282CrossRefGoogle Scholar
  17. 17.
    Skiest DJ, Crosby C (2003) Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS 17:1787–1793CrossRefGoogle Scholar
  18. 18.
    Barta SK, Samuel MS, Xue X, Wang D, Lee JY, Mounier N et al (2015) Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Ann Oncol 26:958–966CrossRefGoogle Scholar
  19. 19.
    Mounier N, Spina M, Gisselbrecht C (2007) Modern management of non-Hodgkin lymphoma in HIV-infected patients. Br J Haematol 136:685–698CrossRefGoogle Scholar
  20. 20.
    Garg N, Rayan J, Adams M, Downs R, Routbort M, McEnery K et al (2018) New search: an architecture for fast analytic search of electronic medical records. http://garglab.com/projects/data-mining/. Accessed 24 Oct 2017
  21. 21.
    Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C et al (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol 19:v1–v88CrossRefGoogle Scholar
  22. 22.
    Surveillance Epidemiology and End Results (SEER) Program (2017) SEER*Stat Database: Incidence—SEER 18 Regs Custom Data (with additional treatment fields), Nov 2016 Sub (2000–2014)—Linked To County Attributes—Total U.S., 1969–2015 Counties, National Cancer Institute, DCCPS, Surveillance Research Program. https://seer.cancer.gov/data-software/documentation/seerstat/nov2016/. Accessed 10 Feb 2018
  23. 23.
    National Cancer Institute (2018) Overview of the SEER Program. https://seer.cancer.gov/about/. Accessed 15 Jan 2018
  24. 24.
    Surveillance Epidemiology and End Results (SEER) Program (2015) Number of persons by race and hispanic ethnicity for SEER participants (2010 Census Data). https://seer.cancer.gov/registries/data.html. Accessed 25 April 2018
  25. 25.
    R Core Team (2018) R: a language and environment for statistical computing Vienna, Austria: R Foundation for Statistical Computing. http://www.R-project.org/. Accessed 25 Apr 2018
  26. 26.
    Surveillance Epidemiology and End Results (SEER) Program (2018) SEER*Stat software version 8.3.5: National Cancer Institute, DCCPS, Surveillance Research Program. http://www.seer.cancer.gov/seerstat. Accessed 21 Jan 2018
  27. 27.
    Haldorsen IS, Espeland A, Larsson EM (2011) Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol 32:984–992CrossRefGoogle Scholar
  28. 28.
    Go JL, Lee SC, Kim PE (2006) Imaging of primary central nervous system lymphoma. Neurosurg Focus 21:E4CrossRefGoogle Scholar
  29. 29.
    Koeller KK, Smirniotopoulos JG, Jones RV (1997) Primary central nervous system lymphoma: radiologic-pathologic correlation. Radiographics 17:1497–1526CrossRefGoogle Scholar
  30. 30.
    DeFilipp Z, Li S, El-Jawahri A, Armand P, Nayak L, Wang N et al (2017) High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer 123:3073–3079CrossRefGoogle Scholar
  31. 31.
    Illerhaus G, Kasenda B, Ihorst G, Egerer G, Lamprecht M, Keller U et al (2016) High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol 3:e388–e397CrossRefGoogle Scholar
  32. 32.
    Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G et al (2006) High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 24:3865–3870CrossRefGoogle Scholar
  33. 33.
    Cranial radiotherapy or intensive chemotherapy with hematopoietic stem Cell rescue for primary central nervous system lymphoma in young patients (PRECIS). ClinialTrials.gov (2018) https://clinicaltrials.gov/ct2/show/NCT00863460. Accessed 9 Mar 2018
  34. 34.
    Wolf T, Kiderlen T, Atta J, Stephan C, Kann G, Brodt HR et al (2014) Successful treatment of AIDS-associated, primary CNS lymphoma with rituximab- and methotrexate-based chemotherapy and autologous stem cell transplantation. Infection 42:445–447CrossRefGoogle Scholar
  35. 35.
    Centers for Disease Control and Prevention (2016) HIV Surveillance. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Accessed 4 Jun 2018
  36. 36.
    Howlader N, Shiels MS, Mariotto AB, Engels EA (2016) Contributions of HIV to Non-Hodgkin Lymphoma Mortality Trends in the United States. Cancer Epidemiol Biomarkers Prev 25:1289–1296CrossRefGoogle Scholar
  37. 37.
    Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B et al (2017) Annual Report to the Nation on the Status of Cancer, 1975–2014, featuring survival. J Natl Cancer Inst.  https://doi.org/10.1093/jnci/djx030 Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Dima Dandachi
    • 1
    • 2
    • 3
  • Quinn T. Ostrom
    • 4
    • 5
  • Insun Chong
    • 6
  • Jose A. Serpa
    • 2
  • Thomas P. Giordano
    • 2
    • 7
  • Carol Kruchko
    • 5
  • Jill S. Barnholtz-Sloan
    • 5
    • 8
  • Nathan Fowler
    • 9
  • Rivka R. Colen
    • 10
    • 11
  • Fanny E. Morón
    • 6
    Email author
  1. 1.Department of Medicine, Division of Infectious DiseasesUniversity of MissouriColumbiaUSA
  2. 2.Department of Medicine, Section of Infectious DiseasesBaylor College of MedicineHoustonUSA
  3. 3.Department of Infectious Diseases, Infection Control and Employee HealthThe University of Texas MD Anderson Cancer CenterHoustonUSA
  4. 4.Duncan Cancer CenterBaylor College of MedicineHoustonUSA
  5. 5.Central Brain Tumor Registry of the United StatesHinsdaleUSA
  6. 6.Department of RadiologyBaylor College of MedicineHoustonUSA
  7. 7.Center for Innovations in Quality, Effectiveness and SafetyMichael E. DeBakey VA Medical CenterHoustonUSA
  8. 8.Case Comprehensive Cancer CenterCase Western Reserve University School of MedicineClevelandUSA
  9. 9.Department of Lymphoma/MyelomaThe University of Texas MD Anderson Cancer CenterHoustonUSA
  10. 10.Department of Diagnostic Radiology, Division of Diagnostic ImagingThe University of Texas MD Anderson Cancer CenterHoustonUSA
  11. 11.Department of Cancer Systems Imaging, Division of Diagnostic ImagingThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations